Oil prices extend losses as traders downplay Russia sanction risks
Investing.com - JMP Securities raised its price target on Privia Health Group Inc (NASDAQ:PRVA) to $30.00 from $29.00 on Friday, while maintaining a Market Outperform rating on the healthcare company’s stock. The new target represents a 38% upside from the current price of $21.81, while InvestingPro analysis suggests the stock is currently fairly valued.
The price target increase follows Privia Health’s announcement on Thursday that its nine Accountable Care Organizations (ACOs) achieved $233 million in total Medicare Shared Savings Program (MSSP) savings for the 2024 performance year.
This represents a 32% increase from the 2023 performance year, which had previously grown savings by 34% over the 2022 performance year.
All nine of Privia’s ACOs earned savings on the approximately 195,000 Medicare beneficiaries under their care, achieving an aggregate savings rate of 9.3%.
Three of the nine ACOs exceeded 50% growth in earned savings per patient, according to JMP’s research note on the company’s performance.
In other recent news, Privia Health Group Inc. reported its Q2 2025 earnings, revealing mixed results. The company fell short of earnings per share (EPS) expectations, posting an EPS of $0.02 compared to the anticipated $0.05, which marks a 60% negative surprise. On the other hand, Privia Health exceeded revenue forecasts, generating $521.15 million, surpassing the expected $467.03 million by 11.59%. In another development, Piper Sandler adjusted its price target for Privia Health, lowering it to $35 from $36 while maintaining an Overweight rating. These recent developments highlight the company’s performance and analyst perspectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.